{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Balasubramanian S"],"funding":["Intramural NIH HHS","Janssen Research and Development"],"pagination":["83-91"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9969735"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["194(1)"],"pubmed_abstract":["We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without ibrutinib. Among 910 of 1114 screened patients with non-germinal centre B cell-like (non-GCB) DLBCL by IHC, the concordance with GEP for non-GCB calls was 82·7%, with 691 (75·9%) identified as activated B cell-like (ABC), and 62 (6·8%) as unclassified. Among 746 of 837 enrolled patients with verified non-GCB DLBCL by IHC, the concordance with GEP was 82·8%, with 567 (76·0%) identified as ABC and 51 (6·8%) unclassified; survival outcomes were similar regardless of COO or treatment, whereas "],"journal":["British journal of haematology"],"pubmed_title":["Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib."],"pmcid":["PMC9969735"],"funding_grant_id":["N/A","ZIA BC010728"],"pubmed_authors":["Vermeulen J","Balasubramanian S","Johnson P","Wilson W","Hodkinson B","Sehn LH","Staudt LM","Carey J","Shreeve SM","Major C","Wang S","Sun S","Zinzani PL","Schaffer M","Gerecitano J"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.","description":"We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without ibrutinib. Among 910 of 1114 screened patients with non-germinal centre B cell-like (non-GCB) DLBCL by IHC, the concordance with GEP for non-GCB calls was 82·7%, with 691 (75·9%) identified as activated B cell-like (ABC), and 62 (6·8%) as unclassified. Among 746 of 837 enrolled patients with verified non-GCB DLBCL by IHC, the concordance with GEP was 82·8%, with 567 (76·0%) identified as ABC and 51 (6·8%) unclassified; survival outcomes were similar regardless of COO or treatment, whereas ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-28T08:07:09.293Z","creation":"2025-04-25T17:00:46.026Z"},"accession":"S-EPMC9969735","cross_references":{"pubmed":["33942292"],"doi":["10.1111/bjh.17450"]}}